Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy.
De-Colle C, Mönnich D, Welz S, Boeke S, Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, Jawad JA, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Bayer C, Belka C, Pigorsch S, Combs SE, Lohaus F, Linge A, Krause M, Baumann M, Zips D, Menegakis A. De-Colle C, et al. Clin Transl Radiat Oncol. 2017 Jul 14;5:28-36. doi: 10.1016/j.ctro.2017.06.004. eCollection 2017 Aug. Clin Transl Radiat Oncol. 2017. PMID: 29594214 Free PMC article.
Residual γH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness.
Menegakis A, De Colle C, Yaromina A, Hennenlotter J, Stenzl A, Scharpf M, Fend F, Noell S, Tatagiba M, Brucker S, Wallwiener D, Boeke S, Ricardi U, Baumann M, Zips D. Menegakis A, et al. Radiother Oncol. 2015 Sep;116(3):480-5. doi: 10.1016/j.radonc.2015.08.006. Epub 2015 Aug 18. Radiother Oncol. 2015. PMID: 26297183 Free article.
SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy.
De-Colle C, Menegakis A, Mönnich D, Welz S, Boeke S, Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, Abu Jawad J, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Belka C, Ganswindt U, Pigorsch S, Combs SE, Lohaus F, Linge A, Krause M, Baumann M, Zips D; DKTK-ROG. De-Colle C, et al. Radiother Oncol. 2018 Jan;126(1):125-131. doi: 10.1016/j.radonc.2017.10.008. Epub 2017 Oct 20. Radiother Oncol. 2018. PMID: 29061496
ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gkika E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke M. Guberina M, et al. Pharmacogenomics J. 2021 Feb;21(1):37-46. doi: 10.1038/s41397-020-0174-1. Epub 2020 Jun 16. Pharmacogenomics J. 2021. PMID: 32546699 Free PMC article.
Correction: ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gkika E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke M. Guberina M, et al. Pharmacogenomics J. 2021 Apr;21(2):273. doi: 10.1038/s41397-020-00193-6. Pharmacogenomics J. 2021. PMID: 33009516 Free PMC article. No abstract available.
47 results